Health and Medicine

As an important part of digital health ecosystem, digital health administration system is the most important part. The system is mainly used to integrate all application technologies, adopt digital statistics of Internet big data, create digital information management of health consultation, detection, treatment, rehabilitation and other projects, realize health data collection, real-time health monitoring, health data analysis, chronic disease prevention and control, and sub-health rehabilitation, and can also seamlessly connect with medical Internet of Things data to form a complete digital health product ecosystem.

Company Overview: DeepKinase Technology Co., Ltd, branded as “Danbai Zhi,” is a functional proteomics technology platform company dedicated to advancing precision medicine and drug discovery. Founded in 2019 by a group of high-level scientists, seasoned industry experts, and successful entrepreneurs, the company boasts a core team with both strong research capabilities and extensive commercialization experience. Leveraging its proprietary and cutting-edge proteomics technologies, DeepKinase has developed and commercialized advanced targeted proteomics products and holds intellectual property for its SH2 super-affinity enrichment technology. The company has independently developed platforms and product lines such as DoTK®, QSure®, and DoDT®. It has established partnerships with multiple hospitals and leading companies, expanding its reach into the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the North American market, and has completed several rounds of funding amounting to hundreds of millions.

Core Business: The company’s primary business includes:

DoTK: Utilizing unique patented technology to analyze tyrosine phosphorylation states, aiding in the understanding of kinase activity and signaling in cancer and immune diseases. DeepKinase has developed several proprietary technologies (with PCT patents) beyond DoTK® (TKI Drug Target Efficacy Proteomics Analysis Platform). These include:

DoTD: PROTAC and molecular glue drug degradation efficacy proteomics analysis platform

DoTF: General drug target analysis platform based on chemical proteomics technology

DoTB: Efficacy biomarker discovery platform based on plasma proteomics technology

These platforms and services cover areas such as MOA analysis, off-target and mis-target analysis, biomarker discovery and validation, precision patient stratification, indication expansion, and companion diagnostic development.

Technical Advantages:

High-Depth and High-Throughput Detection of Key Target Proteins: Achieves deep and extensive analysis of critical target proteins.

High Affinity for pTyr: Affinity for pTyr is increased by a factor of a thousand.

High Throughput: Provides comprehensive results in a single test.

Cost-Effective Large-Scale Production: Capable of large-scale expression and purification at a low cost.

Discovery of Novel Tyrosine Phosphorylation Sites: Identifies new biomarkers and targets.

Fully Proprietary Core Technology: Global PCT patents.

Traditional phosphorylation antibody detection techniques require starting from the complete protein structure, which imposes significant limitations on sample types and reduces clinical accessibility. In contrast, DeepKinase’s DoTK® technology platform overcomes these limitations. It is not affected by sample protein denaturation, allowing detection from a wider range of sample types, including fresh frozen tissues, formalin-fixed samples, and paraffin-embedded sections. This enhancement provides stronger clinical accessibility, facilitating the collection of comprehensive functional activity data and immunoactivity data from clinical samples.

Market Positioning: DeepKinase serves global pharmaceutical companies, biotechnology firms, and medical research institutions, focusing on providing high-quality proteomics analysis services. The company has established a robust collaborative network in the global market, actively expanding its international business, with significant market potential in BRICS countries.

Future Vision: DeepKinase aims to become a global leader in the field of proteomics analysis. In the future, the company will continue to increase its investment in R&D, drive technological innovation, and expand its international market presence, supporting the advancement of precision and personalized medicine. Additionally, the company will actively fulfill its corporate social responsibility, promoting progress in medicine and health, improving public health levels, and contributing to sustainable societal development.

This project aims to build a comprehensive ecological closed-loop industrial chain for mugwort, making it a new-generation technology service-oriented project that integrates cultivation, technology promotion, product development, advanced processing, warehousing, logistics, trade sales, community healthcare, and terminal chains. The project is dedicated to bringing high-quality mugwort products and moxibustion services to every individual, family, and community, promoting traditional Chinese medicine culture and creating a mugwort world of health and technology.

Physical therapy for the top ten problems of scalp health, scalp anti-aging, nourishing instead of dyeing.
Insured by Pacific Insurance Company for 3 million, it is nature-friendly, gentle, and non-irritating.

With POCT LFT technology to provide easy of use and low cost Rapid test products to health screening purpose.

“WeParkLife” is the world’s first leisure sports model brand created by Chengdu Happy Sports Development Group through innovative Sino-Finnish and Sino-Dutch cooperation. It encompasses sports park brand projects such as China’s first leading brand in community smart football, “WePark Community Smart Football Park,” and China’s first leading brand in parent-child sports and tourism, “WePark Holistic Sports Park.” “WePark Life” is an international benchmark brand for new-type leisure sports parks, built upon the decade-long practice of the Sino-Finnish-Dutch sports industry alliance under the “Happy Sports China Plan.” It has received strong support from the officials of Finland and the Netherlands.

Regenerative medicine is mainly used in oral repair, wound scar free repair, medical and beauty repair products and high-end cosmetics. The company has conquered the research and development and application of oral materials. At present, it has 10 patents and more than 10 product approvals. It has 3 regenerative medicine scientists and academicians, 1 scientist shareholder and 5 doctoral students. The company is planning to establish a regenerative medicine academician, postdoctoral workstation, national regenerative medicine research center

« WestVac Biopharma Co., Ltd. was established in 2020, co-founded by Academician Wei Yuquan, Ms. Liu Jin and other 10 scientists from Sichuan University. Westvac has become top tier institute on Covid 19 vaccine R&D, production and distributor in the world. Westvac Biopharma became the first approved XBB vaccine provider in June 2023 worldwide. « Westvac is dedicated to the development of cutting-edge biotechnologies for the prevention and treatment of major diseases, including infectious diseases, malignant tumors and other diseases. It is an innovative biopharmaceutical enterprise integrating vaccine and drug research and development, production, and distribution. « Westvac raised USD400mm for its R&D and production facilitators. The shareholders include prominent financial investors as well as top tier Chinese pharma companies. « Westvac has been successfully named as a unicorn enterprise for 4 consecutive years from 2021 to 2024 and is also a national high-tech enterprise in China.